Skip to main content Skip to navigation
BV421 Mouse Anti-Human CD262 (TRAIL-R2)
BV421 Mouse Anti-Human CD262 (TRAIL-R2)

Flow cytometric analysis using BD OptiBuild™ BV421 Mouse Anti-Human CD262 (TRAIL-R2) antibody (Cat. No. 744768; solid line histogram) on live U937 cells, with corresponding Isotype Control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.

Flow cytometric analysis using BD OptiBuild™ BV421 Mouse Anti-Human CD262 (TRAIL-R2) antibody (Cat. No. 744768; solid line histogram) on live U937 cells, with corresponding Isotype Control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.

Product Details
Down Arrow Up Arrow

BD OptiBuild™
Human (Tested in Development)
Mouse BALB/c IgG1
Flow cytometry (Qualified)
0.2 mg/ml
VIII 80062
Aqueous buffered solution containing ≤0.09% sodium azide.

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV421 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at
  7. Please refer to for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
  10. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
744768 Rev. 2
Antibody Details
Down Arrow Up Arrow

The B-K29 monoclonal antibody specifically binds to CD262 which is also known as, TNF-related apoptosis-inducing ligand receptor 2 (TRAIL Receptor 2, TRAIL-R2), Death receptor 5 (DR5), TRICK2, or KILLER. CD262 is a type I transmembrane protein that is encoded by TNFRSF10B (Tumor necrosis factor receptor superfamily, member 10b). CD262 forms a homotrimeric receptor complex that can bind homotrimeric TRAIL (CD253/APO-2 Ligand) and transduce apoptotic signals intracellularly through its cytoplasmic death domain (DD). CD262 is differentially expressed on cells from a wide variety of normal tissues and tumors. CD262 expression is upregulated by Interferon-α (IFN-α).

The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.

744768 Rev. 2
Format Details
Down Arrow Up Arrow
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Violet 405 nm
407 nm
423 nm
744768 Rev.2
Citations & References
Down Arrow Up Arrow

Development References (6)

  1. Bisgin A, Terzioglu E, Aydin C, et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010; 11(192):200. (Biology). View Reference
  2. Ch'en PF, Xu XG, Liu XS, et al. Characterisation of monoclonal antibodies to the TNF and TNF receptor families. Cell Immunol. 2005; 236(1-2):78-85. (Clone-specific: Flow cytometry). View Reference
  3. Chen C, Liu Y, Zheng D. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Res. 2009; 19(8):984-995. (Biology). View Reference
  4. El-Gazzar A, Perco P, Eckelhart E et al. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9(4):1007-1018. (Biology). View Reference
  5. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006; 26(19):7046-7055. (Clone-specific: Flow cytometry). View Reference
  6. Vermot-Desroches C, Sergent E, Bonnin B, Wijdenes J. Characterization of monoclonal antibodies directed against trail or trail receptors. Cell Immunol. 2005; 236(1-2):86-91. (Clone-specific: Blocking, Flow cytometry, Functional assay, Inhibition). View Reference
View All (6) View Less
744768 Rev. 2

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.